Arixa Pharmaceuticals
We Develop Oral Antibiotics

News & Publications

News & Publications


Arixa Pharmaceuticals Completes $8 Million Seed Funding

PALO ALTO, CA, TUES., MAY 1, 2018 

Gormley’s Take: Startups Seek to Conquer Antibiotic Market Challenges 

By BRIAN GORMLEY, The Wall Street Journal, Fri., Oct. 5, 2018 

Orally Absorbed Derivatives of the β‐Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs

By Eric M. Gordon, Matthew A. J. Duncton, and Mark A. Gallop, Journal of Medicinal Chemistry, Oct. 8, 2018

First Oral Antibiotic Booster for Four Decades Could Tackle Drug Resistance

By Gege Li, Chemistry World, Nov. 2, 2018

Arixa Pharmaceuticals Announces Publication of Seminal Paper Demonstrating First Oral Prodrug of Avibactam

Palo Alto, CA, Nov. 8, 2018

The Hunt for New Antibiotics Grows Harder as Resistance Builds

By MEGHA SATYANARAYANA, C&E News, Dec. 10, 2018